60759-61-7

Upstream product

• 6632-05-9 2,5-diphenyl-1,2-dihydro-pyrazol-3-one 
• 110-46-3 isopentyl nitrite 
• 100-63-0 phenylhydrazine 
• 4845-49-2 1,3-diphenyl-5-oxo-4,5-dihydro-1H-pyrazole 

Downstream Products

• 82428-92-0 (C₃N₂(NO)(C₆H₅)2(O))2(3-picoline)2Zn(II) 
• 82428-84-0 (C₃N₂(NO)(C₆H₅)2(O))2(3-picoline)2Ni(II) 
• 82428-88-4 (C₃N₂(NO)(C₆H₅)2(O))2(pyridine)2Zn(II) 
• 82445-31-6 (C₃N₂(NO)(C₆H₅)2(O))2(pyridine)2Ni(II) 

Relevant academic research and scientific papers

Diastereoselective synthesis of indolenine-based spiro[pyrazolone-4,2′-pyrrolidine] scaffolds: Via 1,3-dipolar cycloaddition of 4-aminopyrazolones, aldehydes, and indolenines

In this work, we report a one-pot [3 + 2] cycloaddition of 4-aminopyrazolones, indolenines, and aldehydes. The reaction utilized in situ generated azomethine ylides as 1,3-dipoles and 2-alkenylindolenines as dipolarophiles affording indolenine-derived spiro[pyrazolone-4,2′-pyrrolidine] scaffolds with four contiguous stereocenters with excellent yields (up to 95%) and diastereoselectivities (up to >20:1 dr) under simple conditions. The in situ generation of azomethine ylides and dipolarophiles in one pot is a unique feature of this process.

Asymmetric Construction of a Multi-Pharmacophore-Containing Dispirotriheterocyclic Scaffold and Identification of a Human Carboxylesterase 1 Inhibitor

A catalytic asymmetric [3 + 2] cyclization of novel 4-isothiocyanato pyrazolones and isatin-derived ketimines was developed, delivering a wide range of intriguing dispirotriheterocyclic products in high yield with excellent diastereoselectivity and enantioselectivity. A chiral sulfoxide derivative of this dispirocyclic product was identified to be a promising hit of the human carboxylesterase 1 inhibitor, and the significant difference of the activity between two enantiomers emphasized the importance of this asymmetric process.

4-isothiocyanate pyrazolone compound

The invention relates to a 4-isothiocyanate pyrazolone compound. The 4-isothiocyanate pyrazolone compound has a structure shown as a general formula I, wherein R1 and R2 are independently selected from C1 to C6 alkyl, phenyl, substituted phenyl, benzene alkyl, thienyl or naphthyl respectively. The compound provided by the invention is synthesized by taking 4-site non-substituted pyrazolone as a raw material through three-step reaction; a preparation method is simple and easy to operate. The compound lays a foundation for constructing a compound with a multi-pharmacophore composite structure, namely pyrazolonespiro[ethylene thiourea]spirooxindole. The formula I is shown in the description.